María Rosario Isabel Luquin Piudo-rekin lankidetzan egindako argitalpenak (9)

2021

  1. A European observational study to evaluate the safety and the effectiveness of safinamide in routine clinical practice: The SynapSES trial

    Journal of Parkinson's Disease, Vol. 11, Núm. 1, pp. 187-198

2020

  1. A Spanish consensus on the use of safinamide for parkinson’s disease in clinical practice

    Brain Sciences, Vol. 10, Núm. 3

  2. Erratum: A Spanish consensus on the use of safinamide for parkinson’s disease in clinical practice. (Brain sci. (2020) 10, 176)

    Brain Sciences

2018

  1. Phenomenology and disease progression of chorea-acanthocytosis patients in Spain

    Parkinsonism and Related Disorders, Vol. 49, pp. 17-21

2012

  1. LRRK2 haplotype-sharing analysis in Parkinson's disease reveals a novel p.S1761R mutation

    Movement Disorders, Vol. 27, Núm. 1, pp. 146-150

2011

  1. LINGO1 gene analysis in Parkinson's disease phenotypes

    Movement Disorders, Vol. 26, Núm. 4, pp. 722-727

2010

  1. Analysis of the GIGYF2 gene in familial and sporadic Parkinson disease in the Spanish population

    European Journal of Neurology, Vol. 17, Núm. 2, pp. 321-325

2009

  1. New MRI, 18F-DOPA and 11C-(+)-α-dihydrotetrabenazine templates for Macaca fascicularis neuroimaging: Advantages to improve PET quantification

    NeuroImage, Vol. 47, Núm. 2, pp. 533-539

2005

  1. Optimization of use of levodopa in Parkinson's disease: Role of levodopa-carbidopa-entacapone combination

    Neurologia, Vol. 20, Núm. 4, pp. 180-188